PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel; Sackler School of Medicine, Aviv University, Aviv, Israel.\', \'Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel; Sackler School of Medicine, Aviv University, Aviv, Israel; Medicine A, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.\', \'Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.\', \'Virology Laboratory, Rambam Health Care Campus, Haifa, Israel.\', \'Department of Hematology, Rambam Health Care Campus, Haifa, Israel.\', \'Department of Hematology, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.\', \'Department of Hematology, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. n_horowitz@rambam.health.gov.il.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3324/haematol.2021.279216
?:hasPublicationType
?:journal
  • Haematologica
is ?:pmid of
?:pmid
?:pmid
  • 34320790
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 3.063
?:rankingScore_hIndex
  • 120
is ?:relation_isRelatedTo_publication of
?:title
  • Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all